Joseph Antin is a Hematology physician affiliated with Boston University. OpenAlex indexes 985 publications with 50,717 citations (h-index 118); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
450 Brookline Ave
Boston, MA 022155418
Telephone
617-632-3667Provider last certified this registry record 11 May 2026.
Clinical trials
- SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
Sponsor: Dana-Farber Cancer Institute
- Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
Sponsor: The Emmes Company, LLC
- Phase I Study of Sequential Cord Blood Transplants
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20254 payments
- Alexion Pharmaceuticals, Inc.Program year20254 payments
- CSL BehringProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
47.7%Kinase inhibitor21.9%Jakafi100%Part D≥15 patientsSelective immunosuppressants17.8%Rezurock100%Part D≥17 patients+ 2 more classes in this area
Anti-infectives
21.1%Short-acting sulfonamides17%Sulfamethoxazole-Trimethoprim100%Part D≥19 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.1%Valacyclovir100%Part D<11 patientsMetabolism & gastrointestinal
15.1%Corticosteroid8.8%Prednisone100%Part D≥13 patientsBile Acid6.3%Ursodiol100%Part D≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 1987–2024 per NIH RePORTER. The latest:
- BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium
Dana-Farber Cancer Inst
FY2024$267,000UG1HL069249 - A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD
Dana-Farber Cancer Inst
FY2023$203,233UG1HL069249 - A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD
Dana-Farber Cancer Inst
FY2022$203,233UG1HL069249
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
New England Journal of Medicine
2017 - Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
Journal of Clinical Oncology
2017 - Ipilimumab for Patients with Relapse after Allogeneic Transplantation
New England Journal of Medicine
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Holick, MD
Boston University
Gene Kwan, MD
Boston University
George O'Connor, MD
Boston University
Gary Balady, MD
Boston University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”